Haleon US Holdings

Subsidiary of Haleon plc (HLN)

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Approved
Nonsteroidal Anti-inflammatory Drug · Adenosine receptor
Migraine
Approved
Nonsteroidal Anti-inflammatory DrugSmall molecule
Migraine

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.